Acino appoints Jostein Davidsen as CEO
Feb 21, 2014
Acino is pleased to
announce, that Jostein Davidsen will join the Acino
Group as its new Chief Executive Officer (CEO) by May 15, 2014, at
the latest.
Since 2012, Jostein Davidsen serves as Head of Emerging Markets
and appointed Corporate Officer at Takeda Pharmaceuticals
International GmbH, based in Zurich (Switzerland). In this
function, he is responsible for the EUR 1.5 billion business in the
emerging growth economies of the Japanese pharmaceutical company
Takeda. Prior to this, Jostein Davidsen had joined Nycomed Pharma
in 1987 and held several senior management positions with the task
of establishing and growing the company's business in Eastern
Europe and the CIS-region. From 1994 to 2011 he built up the
business in Russia-CIS to over EUR 500 million. In recognition of
his outstanding achievements, Jostein Davidsen was nominated to the
Top 100 Pharma Leader Award 2013/2014 as runner-up in the category
Emerging Markets by Scrip Intelligence, the leading source of news
and strategic analysis for the global pharmaceutical industry.
Håkan Björklund, Chairman of Acino Holding AG, commented: "We
are delighted that Jostein Davidsen will join our company as its
new CEO. His extensive experience as a leader in the pharmaceutical
industry and his impressive track record in the emerging markets
will be most valuable for the future development of our
company."
About Acino
Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops,
manufactures and internationally markets well-proven and innovative
pharmaceuticals in novel drug delivery forms. Acino is a leader in
advanced drug delivery technologies with a focus on modified
release oral forms, oral dispersible forms, transdermal systems and
extended release parenterals, for which it also holds patents. As a
partner of pharmaceutical companies worldwide, Acino supplies
finished in-house developed products and/or provides customized
one-stop solutions from product development and registration to
contract manufacturing, packaging and logistics. Under the brand
"Acino Switzerland", Acino markets Swiss-quality medicines in up
and coming economies, currently 80 countries in the Middle East,
Africa, Latin America and Asia. The Acino Group is headquartered in
Aesch BL.
On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned
subsidiary of Avista Capital Partners and Nordic Capital,
successfully completed its public tender offer for Acino Holding
AG. Pharma Strategy Partners GmbH intends to effect a full takeover
of Acino, and will delist the Acino shares from the stock
exchange.
Contact
Robert Schmid
Media & Investor Relations
Phone +41 61 338 61 15
robert.schmid@acino-pharma.com
About Nordic Capital Private Equity Funds
Since the start in 1989, Nordic Capital Private Equity Funds
have invested in large and medium sized companies, primarily in
Northern Europe. Through committed ownership and by targeting
strategic development and operational improvements, Nordic Capital
creates value in its investments. The funds invest in companies in
Northern Europe and in selected investment opportunities
internationally. They are based in Jersey, Channel Islands, and are
advised by the NC Advisory companies in Sweden, Denmark, Finland,
Norway, Germany and the UK. Additional information about Nordic
Capital is available through its corporate website, www.nordiccapital.com.
Back to news listings >
